NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis

RecruitingPhase 3

Sponsor: Marc Blondon

Conditions: Venous Thromboembolism (VTE), Postpartum

Interventions: Low-dose low-molecular-weight heparin

Countries: Switzerland

The goal of this clinical trial is to evaluate the risk-benefit of a short-term treatment with a low-dose low-molecular-weight heparin (LMWH), in the postpartum period (after delivery). The main questions it aims to answer are: * compared to no treatment, does short-term postpartum LMWH modify the risk of venous thromboembolism within 90 days of delivery? * compared to no treatment, does short-term postpartum LMWH modify the risks of bleeding and wound complications? Participants will take low-dose LMWH for 7-10 days or no treatment, and will be followed for 90 days post-delivery.

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria: postpartum women after delivery AND ≥1 major risk factor / ≥2 minor risk factors:

* Major risk factors: Emergency cesarean section ; Pre-pregnancy BMI ≥35kg/m2 ; Known low-risk thrombophilia (heterozygous factor V Leiden; heterozygous G20210 prothrombin mutation) ; Pre-eclampsia ; Pre-term delivery ; Peripartum systemic infection ; Intra-uterine growth restriction ; Pregnancy loss
* Minor risk factors: Age ≥35 years ; Pre-pregnancy BMI 30.0-34.9kg/m2 ; Current smoking ; Elective cesarean section ; Postpartum hemorrhage ; Antenatal immobility

Exclusion Criteria:

* ≥2 doses of postpartum LMWH
* Any indication for therapeutic anticoagulation
* A high-risk of postpartum VTE
* An increased bleeding risk
* A contra-indication to heparin

Locations (8)

Baden, Switzerland
Basel, Switzerland
Bern, Switzerland
Geneva, Switzerland
Lausanne, Switzerland
Lugano, Switzerland
Neuchâtel, Switzerland
Sion, Switzerland